Shots:

• The P-III COSMIC-313 study involves assessing of Cabometyx (cabozantinib) + Opdivo (nivolumab) + Yervoy (ipilimumab) vs nivolumab+ ipilimumab + PBO in 676 patients in the ratio (1:1) with previously untreated advanced RCC across 150 sites globally
• The P-III COSMIC-313 study follows ongoing P-Ib study assessing cabozantinib + nivolumab with/without ipilimumab in patients with advanced genitourinary cancers including RCC- previously treated with sorafenib
• Cabometyx is a tyrosine kinase inhibitor promoting an immune-permissive environment in combination with immune checkpoint inhibitors and is approved in the US for HCC & advanced RCC. Opdivo & Yervoy are checkpoint inhibitors developed by BMS

Ref: Exelixis | Image: Brand Navigation